A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo

References

• Dong H, Ji X, Wang Y, Meng L, Chen D, Feng W. Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol 2015; 13:189; PMID:26016480; http://dx.doi.org/10.1186/s12957-015-0605-7
   PubMed Web of Science ®Google Scholar
• Vanderstraeten A, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F, Tuyaerts S. In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer. J Immunother 2015; 38:239-49; PMID:26049547; http://dx.doi.org/10.1097/CJI.0000000000000085
   PubMed Web of Science ®Google Scholar
• Pluta P, Jeziorski A, Cebula-Obrzut AP, Wierzbowska A, Piekarski J, Smolewski P. Expression of IAP family proteins and its clinical importance in breast cancer patients. Neoplasma 2015; 62:666-73; PMID:25997966; http://dx.doi.org/10.4149/neo_2015_080
   PubMed Web of Science ®Google Scholar
• Danilewicz M, Stasikowska-Kanicka O, Wągrowska-Danilewicz M. Augmented immune expression of survivin correlates with parameters of aggressiveness in prostate cancer. Pol J Pathol 2015; 66:44-8; PMID:26017879; http://dx.doi.org/10.5114/pjp.2015.51152
   PubMed Web of Science ®Google Scholar
• Xiao M, Wang J, Lin Z, Lu Y, Li Z, White SW, Miller DD, Li W. Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties. PLoS One 2015; 10:e0129807; PMID:26070194; http://dx.doi.org/10.1371/journal.pone.0129807
   PubMedGoogle Scholar
• Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, Han H, Hao X. Knockdown of Survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 2009; 41:223-30; PMID:19280061; http://dx.doi.org/10.1093/abbs/gmp005
   PubMed Web of Science ®Google Scholar
• Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R. Achieving successful delivery of oligonucleotides - From physico-chemical characterization to in vivo evaluation. Biotechnol Adv 2015; 33:1294-309; PMID:25916823; http://dx.doi.org/10.1016/j.biotechadv.2015.04.008
   PubMed Web of Science ®Google Scholar
• Juliano RL, Alahari S, Yoo H, Kole R, Cho M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides, Pharm Res 16:494-502; PMID:10227702; http://dx.doi.org/10.1023/A:1011958726518
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65:36-48; PMID:23036225; http://dx.doi.org/10.1016/j.addr.2012.09.037
   PubMed Web of Science ®Google Scholar
• Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 2015; 88:20150207; PMID:25969868; http://dx.doi.org/10.1259/bjr.20150207
   PubMed Web of Science ®Google Scholar
• Kopeček J. Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev 2013; 65:49-59; PMID:23123294; http://dx.doi.org/10.1016/j.addr.2012.10.014
   PubMed Web of Science ®Google Scholar
• Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10:310-5; PMID:14770178; http://dx.doi.org/10.1038/nm996
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich Peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 276:5836-5840; PMID:11084031; http://dx.doi.org/10.1074/jbc.M007540200
   PubMed Web of Science ®Google Scholar
• Ruczynski J, Wierzbicki PM, Kogut-Wierzbicka M, Mucha P, Siedlecka-Kroplewska K, Rekowski P. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells. Folia Histochem Cytobiol 2014; 52:257-69; PMID:25530464; http://dx.doi.org/10.5603/FHC.a2014.0034
   PubMed Web of Science ®Google Scholar
• Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272:16010-7; PMID:Can't; http://dx.doi.org/10.1074/jbc.272.25.16010
   PubMed Web of Science ®Google Scholar
• Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009; 27:567-71; PMID:19448630; http://dx.doi.org/10.1038/nbt.1541
   PubMed Web of Science ®Google Scholar
• Eguchi A, Dowdy SF. Efficient siRNA delivery by novel PTD-DRBD fusion proteins. Cell Cycle 2010; 9:424-5; PMID:20090414; http://dx.doi.org/10.4161/cc.9.3.10693
   PubMed Web of Science ®Google Scholar
• Palm-Apergi C, Eguchi A, Dowdy SF. PTD-DRBD siRNA delivery. Methods Mol Biol 2011; 683:339-47; PMID:21053141; http://dx.doi.org/10.1007/978-1-60761-919-2_24
   PubMedGoogle Scholar
• Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons Curr Med Chem. 2011; 18:4206-14; PMID:21838685; http://dx.doi.org/10.2174/092986711797189600
   PubMedGoogle Scholar
• Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, Bawa R, Kanwar RK. Nucleic Acid-Based Aptamers: Applications, Development And Clinical Trials. Curr Med Chem 2015; 22:2539-57; PMID:25723512; http://dx.doi.org/10.2174/0929867322666150227144909
   PubMed Web of Science ®Google Scholar
• Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62:4029-33; PMID:12124337; http://dx.doi.org/10.1158/0008-5472
   PubMed Web of Science ®Google Scholar
• McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24:1005-15; PMID:16823371; http://dx.doi.org/10.1038/nbt1223
   PubMed Web of Science ®Google Scholar
• Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010; 31:4592-9; PMID:20206379; http://dx.doi.org/10.1016/j.biomaterials.2010.02.030
   PubMed Web of Science ®Google Scholar
• Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Stockdale KR, Nat Biotechnol 2009; 27:839-49; PMID:19701187; http://dx.doi.org/10.1038/nbt.1560
   PubMed Web of Science ®Google Scholar
• Ryter JM, Schultz SC. Molecular basis of double-stranded RNA-protein interactions: structure of a dsRNA-binding domain complexed with dsRNA. EMBO J 1998; 17:7505-13; PMID:9857205; http://dx.doi.org/10.1093/emboj/17.24.7505
   PubMed Web of Science ®Google Scholar
• Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010; 28:570-9; PMID:20833440; http://dx.doi.org/10.1016/j.tibtech.2010.07.009
   PubMed Web of Science ®Google Scholar
• Lu H, Wang D, Kazane S, Javahishvili T, Tian F, Song F, Sellers A, Barnett B, Schultz PG. Site-specific antibody-polymer conjugates for siRNA delivery. J Am Chem Soc 2013; 135:13885-91; PMID:23924037; http://dx.doi.org/10.1021/ja4059525
   PubMed Web of Science ®Google Scholar
• Cuellar TL, Barnes D, Nelson C, Tanguay J, Yu SF, Wen X, Scales SJ, Gesch J, Davis D, Siebel CW, et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res 2015; 43:1189-203; PMID:25550431; http://dx.doi.org/10.1093/nar/gku1362
   PubMed Web of Science ®Google Scholar
• Kruspe S, Mittelberger F, Szameit K, Hahn U. Aptamers as drug delivery vehicles. ChemMedChem 2014; 9:1998-2011; PMID:25130604; http://dx.doi.org/10.1002/cmdc.201402163
   PubMed Web of Science ®Google Scholar
• Chen A, Yang S. Replacing antibodies with aptamers in lateral flow immunoassay. Biosens Bioelectron 2015; 71:230-242; PMID:25912679; http://dx.doi.org/10.1016/j.bios.2015.04.041
   PubMed Web of Science ®Google Scholar
• Toh SY, Citartan M, Gopinath SC, Tang TH. Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay. Biosens Bioelectron 2014; 64C:392-403; PMID:25278480; http://dx.doi.org/10.1016/j.bios
   Google Scholar
• Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Gao S, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 2011; 6:1747-56; PMID:21980237; http://dx.doi.org/10.2147/IJN
   PubMed Web of Science ®Google Scholar
• Wen X, Wang K, Zhao Z, Zhang Y, Sun T, Zhang F, Wu J, Fu Y, Du Y, Song Y, et al. Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticles. PLoS One 2014; 9:e106652; PMID:25187980; http://dx.doi.org/10.1371/journal.pone.0106652
   PubMedGoogle Scholar
• Niu F, Yao H, Liao K, Buch S. HIV Tat 101-mediated loss of pericytes at the blood-brain barrier involves PDGF-BB. Ther Targets Neurol Dis 2015; 2:e471; PMID:26023685; http://dx.doi.org/10.14800/ttnd.471
   PubMedGoogle Scholar
• Patel RC, Stanton P, McMillan NM, Williams BR, Sen GC. The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo. Proc Natl Acad Sci USA 1995; 92:8283-7; PMID:7545299; http://dx.doi.org/10.1073/pnas.92.18.8283
   PubMed Web of Science ®Google Scholar
• Nanduri S, Carpick BW, Yang Y, Williams BR, Qin J. Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J 1998; 17:5458-65; PMID:9736623; http://dx.doi.org/10.1093/emboj/17.18.5458
   PubMed Web of Science ®Google Scholar
• Tian B, Bevilacqua PC, Diegelman-Parente A, Mathews MB. The double-stranded-RNA-binding motif: interference and much more. Nat Rev Mol Cell Biol 2004; 5:1013-23; PMID:15573138; http://dx.doi.org/10.1038/nrm1528
   PubMed Web of Science ®Google Scholar
• Sano T, Cantor CR. Expression of a cloned streptavidin gene in Escherichia coli. Proc Natl Acad Sci USA 1990; 87:142-6; PMID:2404273; http://dx.doi.org/10.1073/pnas.87.1.142
   PubMed Web of Science ®Google Scholar
• Sano T, Pandori MW, Chen X, Smith CL, Cantor CR. Recombinant core streptavidins. A minimum-sized core streptavidin has enhanced structural stability and higher accessibility to biotinylated macromolecules. J Biol Chem 1995; 270:28204-9; PMID:7499314; http://dx.doi.org/10.1074/jbc.270.36.21354
   PubMed Web of Science ®Google Scholar
• Qureshi MH, Yeung JC, Wu SC, Wong SL. Development and characterization of a series of soluble tetrameric and monomeric streptavidin muteins with differential biotin binding affinities. J Biol Chem 2001; 276:46422-8; PMID:11584006; http://dx.doi.org/10.1074/jbc.M107398200
   PubMed Web of Science ®Google Scholar